Walter E. Washington Convention Center
Washington, D.C.
May 16-19, 2022

SIRION Biotech

Graefelfing,  Bavaria 
  • Booth: 218

Your expert partner for viral vector development for CGT!

SIRION Biotech is Europe’s leading supplier of viral vector technologies (AAV, LV, AV).

We guide our customer through the entire CGT value chain – from capsid evolution and clinical vector design to reduce vector dose and improve therapeutic success, to sharing our expertise in process development and manufacture of high-quality clinically compliant viral vectors for late preclinical applications.

We also offer LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cells.

Brands: LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cells


  • LentiBOOST®
    A highly effective transduction enhancer for clinical application of lentiviral vectors – receptor-independent, facilitates fusion of lentivirus with the cell membrane, increases vector copy number, and significantly improves transduction efficiency...

  • LentiBOOST® can be applied to a wide range of clinically relevant cell types, including CD34+ hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), neuronal stem cells, primary T cells, hard-to-transduce murine T cells, NK cells, and fibroblasts. It is ideal for clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

    LentiBOOST offers many benefits for drug development, including increased and titratable vector copy number per cell and increased safety in line with FDA/EMA criteria.

    Its successful track record includes integration into more than 20 Phase I/II and III clinical trials in the US and Europe as well as manufacturing of an approved product.